MCID: CRY014
MIFTS: 46

Cryptococcal Meningitis

Categories: Neuronal diseases

Aliases & Classifications for Cryptococcal Meningitis

MalaCards integrated aliases for Cryptococcal Meningitis:

Name: Cryptococcal Meningitis 12 15 17
Meningitis, Cryptococcal 44 72
Meningitis Cryptococcal 55

Classifications:



External Ids:

Disease Ontology 12 DOID:0080159
MeSH 44 D016919
UMLS 72 C0085436

Summaries for Cryptococcal Meningitis

Disease Ontology : 12 A fungal meningitis that has material basis in Crypococcus fungal infection.

MalaCards based summary : Cryptococcal Meningitis, also known as meningitis, cryptococcal, is related to meningitis and cryptococcosis. An important gene associated with Cryptococcal Meningitis is IFNG (Interferon Gamma), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Amphotericin B and Stavudine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and liver, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 75 Cryptococcosis, is a potentially fatal fungal disease. It is caused by one of two species; Cryptococcus... more...

Related Diseases for Cryptococcal Meningitis

Diseases related to Cryptococcal Meningitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 299)
# Related Disease Score Top Affiliating Genes
1 meningitis 32.4 MBL2 IFNG ADA
2 cryptococcosis 31.9 MBL2 IFNG
3 bacterial infectious disease 30.6 MBL2 IFNG CSF2
4 miliary tuberculosis 30.5 IFNG ADA
5 cytomegalovirus retinitis 30.4 IFNG CSF2
6 extrapulmonary tuberculosis 30.4 IFNG ADA
7 pericarditis 30.2 IFNG ADA
8 pulmonary tuberculosis 30.0 MBL2 IFNG ADA
9 pulmonary sarcoidosis 29.8 IFNG CSF2
10 macroglobulinemia 28.8 TNFSF13B TNFRSF13C TNFRSF13B
11 systemic lupus erythematosus 28.1 TNFSF13B TNFRSF13C TNFRSF13B MBL2 IFNG FCGR2B
12 aids - neurological complications 11.5
13 acquired immunodeficiency syndrome 10.8
14 intracranial hypertension 10.7
15 immune deficiency disease 10.7
16 hydrocephalus 10.7
17 congenital hydrocephalus 10.7
18 human immunodeficiency virus type 1 10.7
19 meningoencephalitis 10.6
20 headache 10.6
21 tuberculous meningitis 10.5
22 lupus erythematosus 10.5
23 papilledema 10.5
24 lymphopenia 10.5
25 large granular lymphocyte leukemia 10.5 IFNG CSF2
26 yemenite deaf-blind hypopigmentation syndrome 10.5
27 trichosporonosis 10.5 IFNG CSF2
28 mucormycosis 10.5 IFNG CSF2
29 ocular motor apraxia 10.5
30 pericardial tuberculosis 10.5 IFNG ADA
31 candida glabrata 10.5 IFNG CSF2
32 fungal meningitis 10.5
33 tuberculous peritonitis 10.4 IFNG ADA
34 human t-cell leukemia virus type 2 10.4 IFNG CSF2
35 carotid artery thrombosis 10.4 IFNG CSF2
36 meconium aspiration syndrome 10.4 IFNG CSF2
37 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.4
38 chronic meningitis 10.4
39 pleural tuberculosis 10.4 IFNG ADA
40 cyclic neutropenia 10.4 IFNG CSF2
41 candidiasis 10.4
42 sarcoidosis 1 10.4
43 lymphocytic leukemia 10.4
44 liver cirrhosis 10.4
45 chronic graft versus host disease 10.4 TNFSF13B IFNG
46 vasculitis 10.3
47 pleurisy 10.3 IFNG ADA
48 neutropenia 10.3
49 leukemia 10.3
50 oral candidiasis 10.3

Comorbidity relations with Cryptococcal Meningitis via Phenotypic Disease Network (PDN):


Acute Cystitis Cryptococcosis
Deficiency Anemia

Graphical network of the top 20 diseases related to Cryptococcal Meningitis:



Diseases related to Cryptococcal Meningitis

Symptoms & Phenotypes for Cryptococcal Meningitis

MGI Mouse Phenotypes related to Cryptococcal Meningitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 ADA ARRB2 CSF2 FCGR2B IFNG MBL2
2 homeostasis/metabolism MP:0005376 9.86 ADA ARRB2 CSF2 FCGR2B IFNG MBL2
3 immune system MP:0005387 9.81 ADA ARRB2 CSF2 FCGR2B IFNG MBL2
4 renal/urinary system MP:0005367 9.43 ADA CSF2 FCGR2B IFNG MBL2 TNFRSF13B
5 respiratory system MP:0005388 9.02 ADA ARRB2 CSF2 FCGR2B IFNG

Drugs & Therapeutics for Cryptococcal Meningitis

Drugs for Cryptococcal Meningitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
2
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
3
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
4
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
5
Zidovudine Approved Phase 4 30516-87-1 35370
6
Nevirapine Approved Phase 4 129618-40-2 4463
7
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
8
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
9 Liposomal amphotericin B Phase 4
10 Anti-Bacterial Agents Phase 4
11 Antiparasitic Agents Phase 4
12 Antiprotozoal Agents Phase 4
13 Cytochrome P-450 CYP3A Inducers Phase 4
14 Cytochrome P-450 Enzyme Inducers Phase 4
15 Nucleic Acid Synthesis Inhibitors Phase 4
16 Reverse Transcriptase Inhibitors Phase 4
17 Anti-HIV Agents Phase 4
18 Anti-Retroviral Agents Phase 4
19 Antiviral Agents Phase 4
20 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
21 Liver Extracts Phase 4
22
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 5281106 54677470
23
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
24
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
26
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
27
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
28
Sertraline Approved Phase 3 79617-96-2 68617
29 Analgesics Phase 3
30 Cyclooxygenase Inhibitors Phase 3
31 Analgesics, Non-Narcotic Phase 3
32 Cyclooxygenase 2 Inhibitors Phase 3
33 Anti-Inflammatory Agents, Non-Steroidal Phase 3
34 Antirheumatic Agents Phase 3
35 Gastrointestinal Agents Phase 3
36 Antiemetics Phase 3
37 Anti-Inflammatory Agents Phase 3
38 HIV Protease Inhibitors Phase 3
39 glucocorticoids Phase 3
40 Antineoplastic Agents, Hormonal Phase 3
41 Peripheral Nervous System Agents Phase 3
42
protease inhibitors Phase 3
43 BB 1101 Phase 3
44 Autonomic Agents Phase 3
45 Antitubercular Agents Phase 3
46 14-alpha Demethylase Inhibitors Phase 3
47 Hormones Phase 3
48 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
49 Cytochrome P-450 Enzyme Inhibitors Phase 3
50 Antifungal Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
2 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
3 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
4 A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis Completed NCT00976040 Phase 4
5 Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex at 10 mg/kg/d for 7 Days or 5.0 mg/kg/d for 14 Days as Induction Therapy for Disseminated Cryptococcosis in Patients With HIV Completed NCT01656382 Phase 4 ABLC
6 Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial. Active, not recruiting NCT03723525 Phase 4
7 Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Sub-Saharan Africa Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Complemented by Repeat Lumbar Punctures Unknown status NCT01715922 Phase 2, Phase 3 Fluconazole;Flucytosine
8 A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
9 Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis Completed NCT01802385 Phase 3 Sertraline
10 Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00001017 Phase 3 Fluconazole;Amphotericin B
11 Rapid Diagnostic Tests in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases in Patients With Neurological Disorders in Rural Hospitals of Bandundu,Democratic Republic of Congo Completed NCT01589289 Phase 3
12 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
13 A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis Recruiting NCT03092817 Phase 3 Dexamethasone
14 Evaluation of CrAg Screening With Enhanced Antifungal Therapy for Asymptomatic CrAg+ Persons Not yet recruiting NCT03945448 Phase 2, Phase 3 Single dose liposomal Amphotericin and Fluconazole;Fluconazole
15 Cryptococcal Antigen Screening Plus Sertraline Terminated NCT03002012 Phase 3 Sertraline;Placebo Oral Tablet;Fluconazole
16 Dexamethasone in Cryptococcal Meningitis Completed NCT00000776 Phase 2 Flucytosine;Fluconazole;Amphotericin B;Dexamethasone
17 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase II Study of the Safety and Antifungal Activity of Subcutaneous Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) in Conjunction With Standard Therapy in Patients With Acute Cryptococcal Meningitis Completed NCT00012467 Phase 2 Itraconazole;Flucytosine;Fluconazole;Amphotericin B;Interferon gamma-1b
18 A Phase II Randomized Trial of Amphotericin B Alone or Combined With Fluconazole in the Treatment of AIDS-Associated Cryptococcal Meningitis Completed NCT00145249 Phase 2 Amphotericin B;Fluconazole
19 A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis Completed NCT00885703 Phase 1, Phase 2 Fluconazole;Amphotericin B
20 Pilot Study To Determine the Feasibility of Itraconazole for Primary Treatment and Suppression of Relapse of Disseminated Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome Completed NCT00000975 Phase 2 Itraconazole
21 A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis Active, not recruiting NCT03112031 Phase 2 Tamoxifen;Amphotericin B;Fluconazole
22 Valganciclovir for Suppression of HHV-8 Four Weeks Prior to Initiation of cART in Patients With Disseminated Kaposi Sarcoma Compare With Standard Therapy, Its Impact on the Development of IRIS and Attributable Mortality Active, not recruiting NCT03296553 Phase 2 Valganciclovir;Antiretroviral Combinations
23 Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial Not yet recruiting NCT04031833 Phase 1, Phase 2 MAT2203;Amphotericin B
24 A Multicenter, Randomized Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00847678 Phase 2
25 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00324025 Phase 2 Mycograb;placebo
26 An Open Label Randomized Controlled Phase IIb Trial to Determine the Safety of Oral Fluconazole in Combination With Flucytosine as Compared to Fluconazole Alone Terminated NCT01562132 Phase 2 Flucytosine and fluconazole;Fluconazole
27 Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis Withdrawn NCT02908334 Phase 2 Sertraline
28 Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report From June 2015 to June 2016 Completed NCT02955862 Phase 1
29 Phase I Study to Evaluate the Safety and Tolerance of RMP-7 Administered With Amphotericin B to Patients With HIV Infection and Cryptococcal Meningitis Completed NCT00002316 Phase 1 Lobradimil;Amphotericin B
30 SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy Completed NCT00000677 Phase 1 SCH 39304
31 A Randomized Study to Evaluate the Safety and Efficacy of Liposomal Amphotericin B and Amphotericin B Deoxycholate With or Without Flucytosine Followed by Fluconazole, for the Treatment of Cryptococcal Meningitis Unknown status NCT02136030 Liposomal amphotericin B;Amphotericin B-deoxycholate
32 A Cross-Sectional Study of HIV-Related Neurological Disorders in Ten Countries of the Asia Pacific Region Unknown status NCT00168246
33 Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002076 Fluconazole
34 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002305 Flucytosine;Fluconazole;Amphotericin B
35 Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002294 Fluconazole
36 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002075 Flucytosine;Fluconazole;Amphotericin B
37 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002074 Fluconazole;Amphotericin B
38 A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002068 Fluconazole;Amphotericin B
39 Multi-Center Evaluation of Fluconazole (UK-49,858) as Treatment for Acute Cryptococcal Meningitis in Patients Who Have Failed to Respond or Have Experienced Unacceptable Toxicity During Treatment With Amphotericin B Completed NCT00002306 Fluconazole
40 An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002077 Fluconazole
41 Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002040 Fluconazole
42 Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome Completed NCT00002019 Amphotericin B, Lipid-based;Amphotericin B
43 A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. Completed NCT00002113 Flucytosine;Fluconazole
44 A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00000639 Itraconazole;Flucytosine;Fluconazole;Amphotericin B
45 Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00000708 Flucytosine;Fluconazole;Amphotericin B
46 Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis. Completed NCT00830856 Fluconazole;Fixed dose - Stavudine, lamivudine and Nevirapine;Fixed dose - Stavudine, Lamivudine, Nevirapine
47 The CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa Through Early Detection and Prevention of Cryptococcal Disease Completed NCT02434172
48 Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy Completed NCT02098525
49 Discontinuation of Primary and Secondary Prophylaxis for Opportunistic Infections in HIV-infected Patients Who Had CD4+ Cell Count <200 Cells/mm3 But Undetectable Plasma HIV-1 RNA Completed NCT01392430
50 Diagnosis of Tuberculous Meningitis by a Secretory Antigenic Target 6 (ESAT-6) in CSF Completed NCT01371916

Search NIH Clinical Center for Cryptococcal Meningitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Amphotericin B
Fluconazole
Fluconazole
Flucytosine

Cochrane evidence based reviews: meningitis, cryptococcal

Genetic Tests for Cryptococcal Meningitis

Anatomical Context for Cryptococcal Meningitis

MalaCards organs/tissues related to Cryptococcal Meningitis:

41
Testes, Brain, Liver, T Cells, Bone, Kidney, Monocytes

Publications for Cryptococcal Meningitis

Articles related to Cryptococcal Meningitis:

(show top 50) (show all 2322)
# Title Authors PMID Year
1
Cerebrospinal fluid adenosine deaminase activity for the diagnosis of tuberculous meningitis in adults. 9 38
17333738 2006
2
Cerebrospinal fluid adenosine deaminase levels in a patient with cryptococcal meningitis. 9 38
1457651 1992
3
[Cryptococcal meningitis in patients with AIDS: combined treatment with amphotericin B and fluconazole, and high levels of adenosine deaminase in cerebrospinal fluid]. 9 38
1620927 1992
4
Basic principles of the virulence of Cryptococcus. 38
31119976 2019
5
Cryptococcosis in the Amazon: A current overview and future perspectives. 38
31181189 2019
6
The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans. 38
31173410 2019
7
The clinical characteristics of adult cryptococcal meningitis patients who died within one year of treatment with a focus on those with early mortality. 38
31227408 2019
8
Causes of Pediatric Meningitis in Botswana: Results From a 16-Year National Meningitis Audit. 38
31261367 2019
9
Apparent performance of metagenomic next-generation sequencing in the diagnosis of cryptococcal meningitis: a descriptive study. 38
31184572 2019
10
Discovery of Simplified Sampangine Derivatives with Potent Antifungal Activities against Cryptococcal Meningitis. 38
31070884 2019
11
Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. 38
31345462 2019
12
HIV-associated cryptococcal meningitis: ongoing challenges and new opportunities. 38
31345446 2019
13
Estimated Burden of Fungal Infections in Namibia. 38
31426392 2019
14
Fluconazole plus flucytosine is a good alternative therapy for non-HIV and non-transplant-associated cryptococcal meningitis: A retrospective cohort study. 38
31120606 2019
15
Advanced HIV: diagnosis, treatment, and prevention. 38
31285181 2019
16
Identification of Pathogen Genomic Differences That Impact Human Immune Response and Disease during Cryptococcus neoformans Infection. 38
31311883 2019
17
Management of human immunodeficiency virus-associated cryptococcal meningitis: Current status and future directions. 38
31365770 2019
18
Clinical characteristics and cerebro-spinal fluid cytokine changes in patients with acquired immunodeficiency syndrome and central nervous system infection. 38
31258689 2019
19
FATAL cryptococcal meningitis in a child with hyper-immunoglobulin M syndrome, with an emphasis on the agent. 38
31409527 2019
20
The Burden of Serious Fungal Infections in Tajikistan. 38
31330914 2019
21
The Burden of Serious Fungal Infections in Kyrgyzstan. 38
31331088 2019
22
Audiologic and Otologic Complications of Cryptococcal Meningoencephalitis in Non-HIV Previously Healthy Patients. 38
31157723 2019
23
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME CAUSING PROGRESSIVE OPTIC NERVE EDEMA IN CRYPTOCOCCAL MENINGITIS. 38
28333858 2019
24
Cryptococcal meningitis presenting as acute flaccid paralysis: A case report. 38
31350098 2019
25
Behind the Leg: Cryptococcal Meningitis, Not Cellulitis. 38
31291565 2019
26
Invasive Cryptococcal Meningitis Presenting as a Skull Base Mass in An Immunocompetent Host: A Case Report. 38
31328082 2019
27
Clinical characteristic of 15 cases of cryptococcal meningitis treated with Ommaya reservoir. 38
31321616 2019
28
Lumbar drainage for the treatment of refractory intracranial hypertension in HIV-negative cryptococcal meningitis. 38
31165635 2019
29
Longitudinal Changes in Cd4+, Cd8+ T Cell Phenotype and Activation Marker Expression Following Antiretroviral Therapy Initiation among Patients with Cryptococcal Meningitis. 38
31319498 2019
30
Cryptococcal Postinfectious Inflammatory Response Syndrome in an Immunocompetent Host. 38
31359947 2019
31
Diagnosis and Management of Central Nervous System Cryptococcal Infections in HIV-Infected Adults. 38
31330959 2019
32
Pathogen Analysis of Central Nervous System Infections in a Chinese Teaching Hospital from 2012-2018: A Laboratory-based Retrospective Study. 38
31209818 2019
33
Long noncoding RNA expression profile from cryptococcal meningitis patients identifies DPY19L1p1 as a new disease marker. 38
30767376 2019
34
A Mimic of Hepatic Encephalopathy: Two Cases of Cryptococcal Meningitis in North America. 38
31293920 2019
35
Factors Associated With Ventriculoperitoneal Shunt Placement in Patients With Cryptococcal Meningitis. 38
31214629 2019
36
Cryptococcal meningitis after ART: Need for proper baseline evaluation in the era of 'Test & Treat'. 38
31049279 2019
37
One year mortality outcomes from the ACTA trial of cryptococcal meningitis treatment in Malawi. 38
31155650 2019
38
Letter to Editor on "Lacunar Stroke in Cryptococcal Meningitis: Clinical and Radiographic Features". 38
30885460 2019
39
Response to Ajay Kumar Mishra, et al. Lacunar strokes in Cryptococcal meningitis. 38
30898446 2019
40
Lacunar Stroke in Cryptococcal Meningitis: Clinical and Radiographic Features. 38
30655043 2019
41
Vision loss in an AIDS patient with cryptococcal meningitis. 38
31032178 2019
42
Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study. 38
31242860 2019
43
Cryptococcal-related mortality despite fluconazole pre-emptive treatment in a cryptococcal antigen (CrAg) screen-and-treat programme. 38
31179488 2019
44
Cryptococcal meningitis: An under-reported disease from the hills of Uttarakhand: A hospital-based cross-sectional study. 38
31334171 2019
45
Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis. 38
31207069 2019
46
An In Vitro Brain Endothelial Model for Studies of Cryptococcal Transmigration into the Central Nervous System. 38
30776307 2019
47
Toward a clinical antifungal peptoid: Investigations into the therapeutic potential of AEC5. 38
30938841 2019
48
Cryptococcal antigenemia and associated risk factors among ART-naïve and ART-experienced HIV-infected peoples at selected health institutions of Mekelle, Northern Ethiopia. 38
30277315 2019
49
Update on fungal infections of the central nervous system: emerging pathogens and emerging diagnostics. 38
30921084 2019
50
Antibody immunity and natural resistance to cryptococcosis. 38
31134140 2019

Variations for Cryptococcal Meningitis

Expression for Cryptococcal Meningitis

Search GEO for disease gene expression data for Cryptococcal Meningitis.

Pathways for Cryptococcal Meningitis

Pathways related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 TNFSF13B TNFRSF13C TNFRSF13B MBL2 IFNG FCGR2B
2
Show member pathways
13.06 YWHAG TNFSF13B TNFRSF13C TNFRSF13B CSF2
3
Show member pathways
12.74 TNFSF13B TNFRSF13C TNFRSF13B IFNG CSF2 ARRB2
4
Show member pathways
12.52 TNFSF13B TNFRSF13C TNFRSF13B IFNG
5
Show member pathways
12.24 YWHAG TNFSF13B TNFRSF13C TNFRSF13B
6
Show member pathways
12.1 TNFSF13B TNFRSF13C TNFRSF13B
7
Show member pathways
11.64 IFNG FCGR2B CSF2
8 11.52 MBL2 FCGR2B
9 11.4 TNFSF13B IFNG CSF2
10 11.01 TNFRSF13B CSF2
11 10.98 IFNG FCGR2B CSF2
12 10.93 TNFSF13B TNFRSF13B
13 10.9 IFNG CSF2
14 10.37 TNFRSF13C TNFRSF13B ADA

GO Terms for Cryptococcal Meningitis

Biological processes related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.81 TNFSF13B TNFRSF13C TNFRSF13B MBL2
2 immune response GO:0006955 9.8 TNFSF13B IFNG FCGR2B CSF2
3 adaptive immune response GO:0002250 9.72 TNFRSF13C TNFRSF13B IFNG
4 regulation of immune response GO:0050776 9.7 TNFSF13B TNFRSF13C FCGR2B
5 tumor necrosis factor-mediated signaling pathway GO:0033209 9.61 TNFSF13B TNFRSF13C TNFRSF13B
6 T cell costimulation GO:0031295 9.56 TNFSF13B TNFRSF13C
7 positive regulation of phagocytosis GO:0050766 9.54 MBL2 FCGR2B
8 negative regulation of B cell proliferation GO:0030889 9.46 TNFRSF13B FCGR2B
9 regulation of circadian sleep/wake cycle, sleep GO:0045187 9.4 CSF2 ADA
10 positive regulation of interleukin-23 production GO:0032747 9.37 IFNG CSF2
11 positive regulation of B cell proliferation GO:0030890 9.33 TNFSF13B TNFRSF13C ADA
12 histamine secretion GO:0001821 9.32 CSF2 ADA
13 B cell costimulation GO:0031296 9.26 TNFSF13B TNFRSF13C
14 regulation of signaling receptor activity GO:0010469 9.18 FCGR2B
15 B cell homeostasis GO:0001782 9.13 TNFSF13B TNFRSF13C TNFRSF13B
16 positive regulation of germinal center formation GO:0002636 8.8 TNFSF13B TNFRSF13C ADA

Molecular functions related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 TNFSF13B IFNG CSF2

Sources for Cryptococcal Meningitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....